Ketamine's Role in Managing Reactive Airway Disease

Clinical Evidence and Guidelines

The American Heart Association notes that ketamine may have substantial efficacy in managing bronchospasm, although randomized trials in children found no benefit when compared with standard care, with a strength of evidence based on case series and small observational studies 1
The standard induction dose of ketamine is 1-2 mg/kg IV, with consideration of using the lower end of the dosing range (1 mg/kg) in hemodynamically unstable patients to minimize hypotension risk while maintaining bronchodilatory benefit, as recommended by clinical guidelines 2
Ketamine's sedative and analgesic properties provide additional utility if intubation is planned in the setting of bronchospasm, and its bronchodilatory effect contributes to maintaining airway patency during the induction period 1

Ketamine maintains hemodynamic stability through sympathomimetic effects, which is advantageous in critically ill patients with reactive airway disease who may be hemodynamically compromised, with a recommended approach based on clinical guidelines 3
Post-intubation hypotension occurs in approximately 18% of emergency department patients receiving ketamine for RSI, and vasopressors should be immediately available, with continuous monitoring of vital signs including heart rate, blood pressure, and oxygen saturation 2
Increased secretions should be managed with suctioning as needed, due to ketamine's stimulation of copious bronchial secretions 1